KNDy neurons in the hypothalamic arcuate nucleus co-release 3 peptides, regulate both reproduction and body temperature, and are normally strongly suppressed by estrogen.KNDy neurons are one of the most beautiful discoveries in neuroendocrinology of the past 15 years — they turned hot flashes from a clinical mystery into a quantifiable mechanism driven by a single neuron group.
Location
· Hypothalamic arcuate nucleus (ARC) — at the base of the third ventricle, against the median eminence · A small group: ~ 2000-5000 neurons bilateral, but with outsized functional impact
'KNDy' = 3 co-released peptides
· K = Kisspeptin (KISS1) — the master switch for GnRH; without it, no puberty · N = Neurokinin B (NKB, encoded by TAC3) — the key downstream mediator, acting through the NK3 receptor; this is fezolinetant's target · Dy = Dynorphin (κ-opioid agonist) — inhibitory, the negative-feedback brake on KNDy itself
· 3 peptides co-expressed in the same neuron — not 3 separate groups; one KNDy neuron synthesizes all 3 peptides and releases them together · K + N = accelerator (excites downstream) · Dy = brake (inhibits self and neighbors)
Two projections
· GnRH neurons (median eminence) — the classic 'reproductive center,' driving pulsatile / release · MnPO (median preoptic nucleus) — the 'thermoregulatory center,' controlling the core temperature set point
· Key: the same KNDy neurons regulate reproduction + body temperature simultaneously. This is why menopause = end of reproduction + hot flashes at the same time.
Normal role of estrogen
· (estradiol) has a strong inhibitory action on KNDy via the ERα receptor · Reproductive years: E2 high → KNDy suppressed → quiet, stable release → wide thermoneutral zone · This is worth stating plainly: estrogen is not only a 'reproductive' hormone — it routinely suppresses a group of temperature-sensitive neurons
Next step: what happens to these neurons when E2 withdraws in perimenopause and menopause.
2 · E2 withdrawal
In perimenopause and menopause ovarian gradually falls to near zero, and KNDy neurons lose their routine suppression, firing more, enlarging and raising NKB expression.Perimenopause + menopause: ovarian output gradually drops to near zero. KNDy neurons lose their routine suppression.
KNDy's response
· Disinhibition → spontaneous firing rate rises · Somatic hypertrophy — first seen by Rance 1990 in postmortem hypothalami of postmenopausal women: arcuate neurons were 30% larger on average, and the group expressing the estrogen receptor was about twice as large; this is the origin of the KNDy hypothesis · NKB + kisspeptin expression ↑ (mRNA measured in ARC) · Dynorphin expression relatively ↓ (brake further weakened)
· Key evidence (Rance et al): comparing premenopausal vs postmenopausal female hypothalamic anatomy, KNDy neurons are markedly hypertrophied, with clearly higher NKB gene expression · Monkey model: ovariectomy → KNDy hypertrophy reproduces; E2 supplementation → returns to normal
Why is it not 'whole-body heat'?
· KNDy is not a global brain neuron; it specifically projects to the MnPO thermoregulatory center · Basal metabolism / temperature set point: unchanged · The 'heat threshold' window narrows abruptly — the core mechanism of the hot flash (next step)
Why does menopause hormone therapy () work for hot flashes?
· E2 directly suppresses KNDy → cools the fire · Transdermal or oral E2, both signal through ER → KNDy → quieting · But MHT carries CV / breast cancer / VTE risk trade-offs (covered in this story's chapter on the hormone-therapy decision) · Wanting a non-hormonal option requires a more precise target — the NK3R, the next step
Why don't all postmenopausal women have severe hot flashes?
· Individual KNDy network sensitivity varies · Genetics (TAC3 receptor polymorphisms) · Body fat: it was long assumed that fat, by turning androgens into estrogens, would ease hot flashes; but among women aged 47 to 59 in the SWAN cohort it went the other way: the higher the body fat, the more women reported hot flashes · Thyroid function + stress level + thermoregulatory thresholds · This is why ~ 80% of perimenopausal women have hot flashes, but severity spans from mild to disabling.
3 · false heat alarm
Overactive KNDy neurons excite the thermoregulatory center via NKB, the thermoneutral zone nearly collapses, and almost any small core-temperature perturbation sets off the full heat-dissipation response, a hot flash.The hot flash (vasomotor symptom, VMS) physiology: exactly like a 'true' heat-stress response, but the trigger is not real heat — it is a KNDy false signal.
Normal thermoregulation
· Core body temperature = POAH (preoptic/anterior hypothalamus) set point ~ 37 °C · Heat threshold (HE) → exceeded → heat dissipation: skin vasodilation + sweating + panting · Cold threshold (CE) → fallen below → heat production: shivering + vasoconstriction · HE - CE = thermoneutral zone, about 0.4 °C wide in postmenopausal women without hot flashes
· KNDy strongly excites MnPO heat-sensitive neurons via NKB → NK3R · MnPO heat-sensitive firing 'misfires' upward · HE threshold drops (POAH thinks it is 'hot') · The 'thermoneutral zone' essentially collapses — measured at 0.0 ± 0.06 °C in symptomatic women vs 0.4 °C in asymptomatic ones (Freedman & Krell 1999)
· Effect: almost any small core-temperature perturbation triggers a heat-dissipation reaction · hot drinks + walking into a warm room + stress + residual menstrual-cycle fluctuations + natural morning rise · The full heat-stress cascade fires without error: skin vasodilation (face / chest / neck most sensitive) → sweating → core temp really drops 0.1-0.3 °C → shivering + goosebumps
Hot-flash curve (single event)
· 0-30 s: skin temperature rises 2-4 °C (vasodilation) · 30 s - 4 min: sweating peak · 4-10 min: core temp falls, shivering / discomfort · Total duration 5-10 min + normal or chilled afterward
Frequency
· Mild: 1-2 / day · Moderate: 5-10 / day · Severe: 10+ / day, with severe night sweats · Median duration ~ 7.4 years (SWAN cohort); for some > 15 years
Hot flashes at night (night sweats)
· A hot flash at night is a night sweat, and it often wakes people up; some, but not all, of the sleep trouble around menopause comes from hot flashes.
4 · Fezolinetant
Fezolinetant blocks NK3 receptors to cut hot flashes, but rare, serious liver injury occurs, so at signs like yellow skin or eyes, stop the drug and seek care at once.Fezolinetant (Veozah): FDA-approved May 2023, the first NK3 receptor antagonist approved by the FDA for hot flashes, directly targeting the KNDy pathway.
Mechanism
· A small-molecule selective NK3R (TACR3) antagonist · Does not enter KNDy itself; instead blocks NKB signal reception on the MnPO · NK3R is mainly expressed on thermoregulatory neurons and in parts of the limbic brain · Does not touch / ER signaling, so none of the hormonal-therapy breast cancer / VTE / CV risks
SKYLIGHT 2 (Johnson 2023, JCEM) key
· N=501 menopausal women with moderate to severe hot flashes, about 11 a day at the start · 3 arms: placebo / fezolinetant 30 mg / fezolinetant 45 mg, 12 weeks · Primary endpoints: frequency and severity of moderate to severe hot flashes · Results at week 12: Flashes per day: placebo -5.0, 30 mg -6.8, 45 mg -7.5; 45 mg cut about 2.5 more a day than placebo (placebo also fell by about 45%)Severity (1-3 scale): placebo -0.48, 45 mg -0.77, about 0.3 points moreOnset: visible from week 1 and held through week 12Safety: rare but serious liver injury has been reported since approval, and a boxed warning was added in December 2024 (see the dosing section below); in the trials, headache and raised liver enzymes were occasionally seen Long-term data: in SKYLIGHT 1 and 2, those who finished the first 12 weeks took the drug for 40 more weeks, and the effect held to week 52 (this phase had no placebo arm); SKYLIGHT 4 was a 52-week randomized, double-blind, placebo-controlled safety trial that found the drug safe and tolerable over 52 weeks
Clinical significance
· First-line non-hormonal option for women with contraindications (breast cancer history / VTE history / high CV risk) · Does not replace MHT — still a second line, priced ~ USD 550/month (US, insurance coverage expanding) · Does not deliver MHT other benefits (bone protection / vaginal atrophy / cardiovascular / metabolic) — fezolinetant only targets VMS
Timeline of "the science of hot flashes"
· 1970-2000: What is a "vasomotor symptom"? Nobody knew — competing hormonal / autonomic hypotheses · 1990 Rance autopsy: KNDy hypertrophy discovered in postmenopausal hypothalamus · 2007-2013: Full KNDy model established in rodents + primates · 2017-2022: NK3R antagonist RCTs (fezolinetant / elinzanetant / pavinetant) · 2023 May: FDA approves fezolinetant — "new mechanism → new drug", a loop closed over 50 years · 2024-2025: elinzanetant (Bayer, dual NK1/NK3R antagonist) phase III RCTs (OASIS 1/2/3) completed; check the latest FDA information for its approval status
Dosing + practical use (no prescription advice here, only description)
· 45 mg orally × 1 / day (with or without food) · Boxed warning (December 2024): rare but serious liver injury; have liver tests on the schedule your doctor sets, and stop the drug and seek care at once for fatigue, poor appetite, nausea, yellow skin or eyes, dark urine and similar signs · Do not use with cirrhosis or severe kidney impairment, or while taking a CYP1A2 inhibitor (such as fluvoxamine) · Do not combine with MHT (no reason to)
"Natural hot-flash supplements" debunked
· Black cohosh: multiple negative, a few small ones positive, overall weak evidence; rare hepatotoxicity · Soy isoflavones: weak-to-moderate evidence, huge individual variability; not the KNDy pathway · Red clover / evening primrose oil / dopamine: almost no evidence · "Bioidentical hormones (BHRT) compounded pharmacy products": not a safer MHT — regulation is absent; FDA-approved MHT already includes "bioidentical" forms
Of everything on this map, fezolinetant is the cleanest modern example of "mechanism-driven drug development" — single neuron group → single pathway → single receptor antagonist → FDA approval. From Rance's 1990 autopsy to 2023 launch: 33 years.